Qu Biologics Inc.

Shirin Kalyan

Harold David Gunn

David W Mullins

Mark Bazett

Dermot McGovern

Ho Pan Sham

Momir Bosiljcic

Marcel Thalen

Monan Angela Zhang

Boyko Traychev Kabakchiev

Therapeutic modalities are provided for targeting adoptive cellular therapies to specific sites of disease, involving the use of specific repertoirs of PRR ligands. In effect, innate immune system signaling is provoked so as to facilitate the homing of adoptive immune cells to sites of disease, for example to the site of a solid tumor.

Innate targeting of adoptive cellular therapies

The invention provides therapeutic compositions that present an artificial repertoire of mammalian pattern recognition receptor (PRR) agonists, so that the pattern of PRR agonists recapitulates a distinct portion of a PRR agonist signature of a mammalian pathogen. The artificial repertoire of PRR agonists may be formulated together in a therapeutic vehicle for combined presentation to an innate immune cell resident in a target tissue in a mammalian host, and the vehicle adapted to deliver the PRR agonists to the target tissue, so as to modulate an immune response.

Therapeutically triggering an innate immune response in a target tissue

Growing community of inventors

Burnaby, Canada

Shirin Kalyan